Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates

Group 1 - Exact Sciences reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of a loss of $0.02 per share, and showing a significant improvement from a loss of $0.09 per share a year ago, resulting in an earnings surprise of +1,200.00% [1] - The company achieved revenues of $811.09 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.78% and increasing from $699.26 million in the same quarter last year [2] - Over the last four quarters, Exact Sciences has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Group 2 - Despite the positive earnings report, Exact Sciences shares have declined approximately 15.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $795.04 million, and for the current fiscal year, it is $0.16 on revenues of $3.1 billion [7] Group 3 - The Zacks Industry Rank indicates that the Medical - Biomedical and Genetics sector is currently in the bottom 42% of over 250 Zacks industries, which may impact the stock's performance [8] - A favorable trend in estimate revisions for Exact Sciences prior to the earnings release has resulted in a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]